Vaccination Impact Against Pneumococcal Disease on Acute Otitis Media Morbidity in Colombian Children < 5 Years of Age
Impact of Vaccination Against Pneumococcal Disease on the Morbidity of Acute Otitis Media in Colombian Children < 5 Years of Age
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bogota, Colombia
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children aged less than five years with record of acute otitis media (with ICD-10 codes: H65 to H66) AND/OR.
- Children aged less than five years with record of pneumonia (with ICD-10 codes: J13 to J18) AND/OR.
- Children aged less than five years with any ICD-10 codes for respiratory diseases (J00-J99).
Exclusion Criteria:
• Not applicable
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Study cohort
The Total population will include all subjects included in the study.
Only aggregated information will be collected for these subjects.
|
Data will be collected retrospectively for cases identified through RIPS*/ DANE** from 2008 until 2014 and through PAI*** from 2009 until 2014.
*Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia.
**Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia.
***Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Occurrence of reported cases of AOM in children below 5 years of age, in post-vaccination period compared to pre-vaccination period of PCV vaccination in UMV
Time Frame: Up to 7 years : from January 2008 to December 2014
|
Up to 7 years : from January 2008 to December 2014
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of reported cases of AOM in children by morbidity, age group, and department in children in post-vaccination period compared to pre-vaccination period of PCV vaccination
Time Frame: Up to 7 years : from January 2008 to December 2014
|
Morbidity including hospitalization, outpatient visits and ICD-10 code type, age groups including 0-24 months and 25-59 months strata.
|
Up to 7 years : from January 2008 to December 2014
|
|
Occurrence of reported cases of pneumonia and acute respiratory infections, overall and by morbidity, age groups, and department in children below 5 years of age before and after implementation of PCV vaccination into the UMV
Time Frame: Up to 7 years : from January 2008 to December 2014
|
morbidity including hospitalization, outpatient visits and ICD-10 code type, age groups including 0-24 months and 25-59 months strata
|
Up to 7 years : from January 2008 to December 2014
|
|
Occurrence of reported deaths due to pneumonia and acute respiratory infections by age group (0-24 months and 25-59 months), department and overall in children below 5 years of age before and after implementation of PCV vaccination into the UMV
Time Frame: Up to 7 years : from January 2008 to December 2014
|
Up to 7 years : from January 2008 to December 2014
|
|
|
Occurrence of AOM related health care resources used and costs* before and after implementation of PCV vaccination into UMV by age group (0-24 months and 25-59 months) and overall
Time Frame: Up to 7 years : from January 2008 to December 2014
|
* Cost calculation (e.g.
medical procedures** , physician visits [outpatient/inpatient and length of stay]) will be extracted from Medical Procedure Cost Manual from the MOH for this analysis: http://www.fasecolda.com/index.php/ramos/soat/tarifas-y-coberturas/manual-tarifario-de-salud/.
** Tympanostomies/myringotomies, myringotomies with insertion of ventilation tubes, etc.
|
Up to 7 years : from January 2008 to December 2014
|
|
Total number of doses (complete or partial) of PCV vaccination administered in infants <1year of age after its introduction into the UMV program in Colombia.
Time Frame: Up to 7 years : from January 2008 to December 2014
|
Up to 7 years : from January 2008 to December 2014
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 203127
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
NCT00610324CompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated Pneumonia
-
NCT03006679WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
NCT07647835Not yet recruitingCommunity Acquired Pneumonia | Childhood Pneumonia
-
NCT06168734WithdrawnHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
NCT07354425CompletedPneumococcal Pneumonia | Community Acquired Pneumonia (CAP)
-
NCT04952337UnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious Organisms
-
NCT03348579CompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired Pneumonia
-
NCT01808092CompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)
-
NCT00543608TerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
NCT03032380CompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)
Clinical Trials on Data collection
-
NCT01890603CompletedHealth Information Technology | Nurse Based Care Management
-
NCT05025969Completed
-
NCT01502150Unknown
-
NCT01365390CompletedInfections, Streptococcal
-
NCT03237299Completed
-
NCT04323709CompletedCardiogenic Shock | Refractory Shock
-
NCT06443333RecruitingMultiple Sclerosis | Myasthenia Gravis | Autoimmune Encephalitis | Acute Disseminated Encephalomyelitis | NMO Spectrum Disorder | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
-
NCT06350656RecruitingCerebrospinal; Disorder
-
NCT02855879CompletedCoronary Artery Bypass Graft | Anomalies in Glucose Metabolism